Source:http://linkedlifedata.com/resource/pubmed/id/17098432
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-12-15
|
pubmed:abstractText |
Molecular modeling studies led to the identification of LFM-A13 (alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide) as a potent inhibitor of Polo-like kinase (Plk). LFM-A13 inhibited recombinant purified Plx1, the Xenopus homolog of Plk, in a concentration-dependent fashion, as measured by autophosphorylation and phosphorylation of a substrate Cdc25 peptide. LFM-A13 was a selective Plk inhibitor. While the human PLK3 kinase was also inhibited by LFM-A13 with an IC(50) value of 61 microM, none of the 7 other serine/threonine kinases, including CDK1, CDK2, CDK3, CHK1, IKK, MAPK1 or SAPK2a, none of the 10 tyrosine kinases, including ABL, BRK, BMX, c-KIT, FYN, IGF1R, PDGFR, JAK2, MET, or YES, or the lipid kinase PI3Kgamma were inhibited (IC(50) values >200-500 microM). The mode of Plk3 inhibition by LFM-A13 was competitive with respect to ATP with a K(i) value of 7.2 microM from Dixon plots. LFM-A13 blocked the cell division in a zebrafish (ZF) embryo model at the 16-cell stage of the embryonic development followed by total cell fusion and lysis. LFM-A13 prevented bipolar mitotic spindle assembly in human breast cancer cells and glioblastoma cells and when microinjected into living epithelial cells at the prometaphase stage of cell division, it caused a total mitotic arrest. Notably, LFM-A13-delayed tumor progression in the MMTV/neu transgenic mouse model of HER2 positive breast cancer at least as effectively as paclitaxel and gemcitabine. LFM-A13 showed a favorable toxicity profile in mice and rats. In particular there was no evidence of hematologic toxicity as documented by peripheral blood counts and bone marrow examinations. These results establish LFM-A13 as a small molecule inhibitor of Plk with in vitro and in vivo anti-proliferative activity against human breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amides,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Recombinant,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/LFM A13,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/polo-like kinase 1
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0968-0896
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
800-14
|
pubmed:dateRevised |
2011-11-2
|
pubmed:meshHeading |
pubmed-meshheading:17098432-Amides,
pubmed-meshheading:17098432-Animals,
pubmed-meshheading:17098432-Antineoplastic Agents,
pubmed-meshheading:17098432-Breast Neoplasms,
pubmed-meshheading:17098432-Cell Cycle Proteins,
pubmed-meshheading:17098432-Cell Line, Tumor,
pubmed-meshheading:17098432-Cell Proliferation,
pubmed-meshheading:17098432-DNA, Recombinant,
pubmed-meshheading:17098432-Disease Progression,
pubmed-meshheading:17098432-Drug Screening Assays, Antitumor,
pubmed-meshheading:17098432-Enzyme Inhibitors,
pubmed-meshheading:17098432-Female,
pubmed-meshheading:17098432-Fluorescence,
pubmed-meshheading:17098432-Humans,
pubmed-meshheading:17098432-Mice,
pubmed-meshheading:17098432-Mice, Inbred BALB C,
pubmed-meshheading:17098432-Mice, Transgenic,
pubmed-meshheading:17098432-Microinjections,
pubmed-meshheading:17098432-Microscopy, Confocal,
pubmed-meshheading:17098432-Models, Molecular,
pubmed-meshheading:17098432-Nitriles,
pubmed-meshheading:17098432-Protein-Serine-Threonine Kinases,
pubmed-meshheading:17098432-Proto-Oncogene Proteins,
pubmed-meshheading:17098432-Rats,
pubmed-meshheading:17098432-Zebrafish
|
pubmed:year |
2007
|
pubmed:articleTitle |
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
|
pubmed:affiliation |
Paradigm Pharmaceuticals, 2139 4th Street, White Bear Lake, MN 55110, USA. fatih_uckun@ih.org
|
pubmed:publicationType |
Journal Article
|